THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Author(s): Sastre-Garriga J, Vila C, Clissold S, Montalban X

Unitat de Neuroimmunologia Clinica, CEM-Cat, Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain. [email protected]

Subject: Multiple Sclerosis View the study


People with multiple sclerosis may present with a wide range of disease symptoms during the evolution of the disease; among these, spasticity can have a marked impact on their well-being and quality of life. Symptom control, including spasticity, remains a key management strategy to improve the patient's well-being and functional status. However, available drug therapies for spasticity sometimes have limited benefit and they are often associated with poor tolerability. Sativex is a 1:1 mix of 9-delta-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, which is available as an oromucosal spray.

Source: Expert Review of Neurotherapeutics (Price: $89)
Share Tweet

More medical studies related to Multiple Sclerosis:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

читать далее